Evidence map›Paper›PMID 40839555›Full record

ArticleMolecular pharmaceutics2025

Nitric Oxide-Releasing Microparticles: A Novel Treatment for Onychomycosis.

Alessandro F Valdez, Jhon Jhamilton Artunduaga Bonilla, Daniel Zamith-Miranda, Bruna Montalvão, Éva Veres, Sirida Youngchim, Clay Tucker, Andrew Draganski, Attila Gácser, Leonardo Nimrichter and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. StudyingPharmaceuticals (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alessandro F ValdezLaboratório de Glicobiologia de Eucariotos, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.ORCID 0000-0002-9285-3670
Jhon Jhamilton Artunduaga BonillaLaboratório de Glicobiologia de Eucariotos, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.
Daniel Zamith-MirandaAlbert Einstein College of Medicine, Departments of Medicine (Division of Infectious Diseases) and Microbiology and Immunology, Bronx, New York 10461, United States.
Bruna MontalvãoLaboratório de Glicobiologia de Eucariotos, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.
Éva VeresDepartment of Biotechnology and Microbiology, University of Szeged, Szeged 6726, Hungary.
Sirida YoungchimDepartment of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Clay TuckerZylö Therapeutics, Greenville, South Carolina 29615, United States.
Andrew DraganskiZylö Therapeutics, Greenville, South Carolina 29615, United States.
Attila GácserDepartment of Biotechnology and Microbiology, University of Szeged, Szeged 6726, Hungary.
Leonardo NimrichterLaboratório de Glicobiologia de Eucariotos, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.ORCID 0000-0001-9281-6856
Joshua D NosanchukAlbert Einstein College of Medicine, Departments of Medicine (Division of Infectious Diseases) and Microbiology and Immunology, Bronx, New York 10461, United States.

Funding

The biology of Cryptococcus neoformans melanizationR01AI171093 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Arturo Casadevall, JOSHUA D NOSANCHUK · 2023 to 2026
$3.2M
Development and optimization of a nitric oxide releasing microparticle-basedtopical treatment for onychomycosisR41AI165204 · NIAID · ZYLO THERAPEUTICS, INC. · PI DRAGANSKI, ANDREW R, NOSANCHUK, JOSHUA D · 2022 to 2023
$600k
Candida auris extracellular vesicles subvert host immune responsesR21AI156104 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI NOSANCHUK, JOSHUA D · 2021 to 2022
$462k
NIAID NIH HHS R01 AI171093NIAID NIH HHS R21 AI156104NIAID NIH HHS R41 AI165204
6 · The paper itself

Abstract

Onychomycosis is one of the most prevalent fungal infections worldwide, resulting in negative effects on general quality of life. Management of the disease encounters a series of obstacles, and antifungal treatment has a low success rate. We aimed to develop and evaluate a novel formulation of NO-releasing microparticles (SNO-MPs) against some of the most common causative agents of onychomycosis:

Indexed as

Antifungal AgentsNitric OxideOnychomycosisArthrodermataceaeAspergillus flavusBiofilmsCandida albicansFibroblastsHumansKeratinocytesMicrobial Sensitivity TestsTrichophytonAntifungal AgentsNitric OxideC. albicansmicroparticlesnitric oxideonychomycosisT. mentagrophytesT. rubrum

Identifiers

PMID40839555
PMCPMC12406251

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.